Nanoviricides Stock Retained Earnings
| NNVC Stock | USD 1.24 0.03 2.36% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess NanoViricides' long-term financial health and intrinsic value.
NanoViricides | Build AI portfolio with NanoViricides Stock |
NanoViricides Company Retained Earnings Analysis
NanoViricides' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current NanoViricides Retained Earnings | (148.84 M) |
Most of NanoViricides' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NanoViricides is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, NanoViricides has a Retained Earnings of (148.84 Million). This is 115.98% lower than that of the Biotechnology sector and 253.61% lower than that of the Health Care industry. The retained earnings for all United States stocks is 101.6% higher than that of the company.
NanoViricides Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NanoViricides' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NanoViricides could also be used in its relative valuation, which is a method of valuing NanoViricides by comparing valuation metrics of similar companies.NanoViricides is currently under evaluation in retained earnings category among its peers.
NanoViricides Fundamentals
| Return On Equity | -0.94 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | 24.24 M | |||
| Shares Outstanding | 19.98 M | |||
| Shares Owned By Insiders | 3.34 % | |||
| Shares Owned By Institutions | 7.94 % | |||
| Number Of Shares Shorted | 117.19 K | |||
| Price To Earning | (6.02) X | |||
| Price To Book | 3.54 X | |||
| EBITDA | (8.72 M) | |||
| Net Income | (9.47 M) | |||
| Cash And Equivalents | 14.07 M | |||
| Cash Per Share | 1.21 X | |||
| Total Debt | 1.31 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 34.92 X | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (8.48 M) | |||
| Short Ratio | 0.44 X | |||
| Earnings Per Share | (0.50) X | |||
| Target Price | 7.0 | |||
| Beta | 1.14 | |||
| Market Capitalization | 25.37 M | |||
| Total Asset | 8.82 M | |||
| Retained Earnings | (148.84 M) | |||
| Working Capital | 364.19 K | |||
| Current Asset | 24.38 M | |||
| Current Liabilities | 6.74 M | |||
| Net Asset | 8.82 M |
About NanoViricides Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NanoViricides's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NanoViricides using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NanoViricides based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out NanoViricides Piotroski F Score and NanoViricides Altman Z Score analysis. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NanoViricides. If investors know NanoViricides will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NanoViricides listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NanoViricides is measured differently than its book value, which is the value of NanoViricides that is recorded on the company's balance sheet. Investors also form their own opinion of NanoViricides' value that differs from its market value or its book value, called intrinsic value, which is NanoViricides' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NanoViricides' market value can be influenced by many factors that don't directly affect NanoViricides' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NanoViricides' value and its price as these two are different measures arrived at by different means. Investors typically determine if NanoViricides is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NanoViricides' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.